IVF sector faces new era of oversight

Australia’s fertility sector faces a regulatory shake-up, as Health Ministers handed down the future of assisted reproductive technologies (ART) oversight at their 12 September meeting.

Ministers considered the outcomes of a rapid review into the ART sector, commissioned in June following the high-profile Monash IVF embryo mix-up. The review concluded that the current self-regulatory model lacks the transparency and rigour expected by governments and the community, particularly as large private equity providers enter the market.

In response, Ministers agreed to reforms aimed at restoring confidence, independence, and transparency. They acknowledged that industry-led accreditation is inadequate and confirmed that the Australian Commission on Safety and Quality in Health Care (ACSQHC) will assume responsibility for independent accreditation of ART services with implementation set for January 2027. State and territory oversight will continue to play a central role in safeguarding consumers and ensuring ethical practice.

The Fertility Society of Australia and New Zealand (FSANZ) acknowledges the outcomes of the Health Ministers’ Meeting.

“We have been open with the challenges of self-regulation in the ART and IVF sector for some time, including inconsistent state and territory requirements for donors, provider registration and complaints handling through legislated authorities, alongside the limits of self-regulation, clear metrics and a lack of enforcement powers under existing law.

“Working within a fragmented system of over 40 laws across Australia, and without the legislated regulatory enforcement powers needed, RTAC and FSANZ have always pushed for the highest standards of safety and accountability possible under the current framework. We will continue to work towards consistent improvement for the benefit of all Australian patients,” the Society said in a statement.

The Health Ministers also endorsed referring relevant legislation to the Australian Law Reform Commission (ALRC) for review, with the goal of modernising and harmonising state laws. This aligns with ongoing ALRC reviews into surrogacy and human tissue regulation.

While immediate steps will be taken to action the recommendations, full implementation will roll out over time to ensure reforms are informed by consumer input and findings from the ALRC review.

“Shifting from self-regulation to an independent oversight model with government participation, must embed transparency, national coordination and stronger enforcement while retaining clinical expertise. This was a key pillar of FSANZ’s recommendations of our 10-year fertility roadmap. 

“We believe a hybrid co-regulation model – with accreditation and oversight managed independently of the Fertility Society but informed by sector expertise and with government participation – offers the right balance between independence, practicality and public trust,” added the Society.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.